ID   T265
AC   CVCL_S805
SY   T265-2c; T265-2C; T265p21
DR   EFO; EFO_0006304
DR   Cosmic; 1644552
DR   Cosmic; 1801808
DR   Cosmic; 2307730
DR   Wikidata; Q54971479
RX   PubMed=9766530;
RX   PubMed=16429615;
RX   PubMed=16510576;
RX   PubMed=21084276;
RX   PubMed=22346343;
RX   PubMed=24726063;
RX   PubMed=28469964;
RX   PubMed=32642732;
RX   PubMed=36818284;
CC   Problematic cell line: Contaminated. Shown to be a ST88-14 derivative (PubMed=36818284).
CC   Doubling time: ~28 hours (PubMed=21084276).
CC   Sequence variation: Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous; Note=By translocation (from parent cell line).
CC   Sequence variation: Gene deletion; HGNC; HGNC:7765; NF1; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:7765; NF1; Simple; p.Arg304Ter (c.910C>T); ClinVar=VCV000187722; Zygosity=Heterozygous; Note=Germline (from parent cell line).
CC   Omics: Transcriptomics; Microarray.
CC   Derived from site: In situ; Retroperitoneal space; UBERON=UBERON_0003693.
ST   Source(s): PubMed=36818284
ST   Amelogenin: X,Y
ST   CSF1PO: 9,12
ST   D13S317: 12
ST   D16S539: 13
ST   D18S51: 12
ST   D19S433: 13,14
ST   D21S11: 29,32.2
ST   D2S1338: 17,23
ST   D3S1358: 15,18
ST   D5S818: 12,13
ST   D7S820: 8
ST   D8S1179: 14
ST   FGA: 21
ST   TH01: 9
ST   TPOX: 11,12
ST   vWA: 16
DI   NCIt; C3798; Malignant peripheral nerve sheath tumor
DI   NCIt; C3273; Neurofibromatosis type 1
DI   ORDO; Orphanet_3148; Malignant peripheral nerve sheath tumor
DI   ORDO; Orphanet_636; Neurofibromatosis type 1
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_8916 ! ST88-14
SX   Male
AG   24Y
CA   Cancer cell line
DT   Created: 03-02-14; Last updated: 10-04-25; Version: 14
//
RX   PubMed=9766530; DOI=10.1002/(SICI)1097-4652(199811)177:2<334::AID-JCP15>3.0.CO;2-9;
RA   Badache A., de Vries G.H.;
RT   "Neurofibrosarcoma-derived Schwann cells overexpress platelet-derived
RT   growth factor (PDGF) receptors and are induced to proliferate by PDGF
RT   BB.";
RL   J. Cell. Physiol. 177:334-342(1998).
//
RX   PubMed=16429615; DOI=10.1017/S1740925X04000274; PMCID=PMC1325299;
RA   Lee P.R., Cohen J.E., Tendi E.A., Farrer R., de Vries G.H.,
RA   Becker K.G., Fields R.D.;
RT   "Transcriptional profiling in an MPNST-derived cell line and normal
RT   human Schwann cells.";
RL   Neuron Glia Biol. 1:135-147(2004).
//
RX   PubMed=16510576; DOI=10.1158/0008-5472.CAN-05-3330;
RA   Miller S.J., Rangwala F., Williams J., Ackerman P., Kong S.,
RA   Jegga A.G., Kaiser S., Aronow B.J., Frahm S., Kluwe L., Mautner V.-F.,
RA   Upadhyaya M., Muir D.F. 4th, Wallace M.R., Hagen J., Quelle D.E.,
RA   Watson M.A., Perry A., Gutmann D.H., Ratner N.;
RT   "Large-scale molecular comparison of human Schwann cells to malignant
RT   peripheral nerve sheath tumor cell lines and tissues.";
RL   Cancer Res. 66:2584-2591(2006).
//
RX   PubMed=21084276; DOI=10.1158/0008-5472.CAN-10-2799; PMCID=PMC3064267;
RA   Lopez G., Torres K.E., Liu J.J.-H., Hernandez B., Young E.D., Belousov R.,
RA   Bolshakov S.V., Lazar A.J.F., Slopis J.M., McCutcheon I.E., McConkey D.J.,
RA   Lev D.C.;
RT   "Autophagic survival in resistance to histone deacetylase inhibitors:
RT   novel strategies to treat malignant peripheral nerve sheath tumors.";
RL   Cancer Res. 71:185-196(2011).
//
RX   PubMed=22346343; DOI=10.4137/TOG.S8830; PMCID=PMC3273949;
RA   Sun D., Tainsky M.A., Haddad R.;
RT   "Oncogene mutation survey in MPNST cell lines enhances the dominant
RT   role of hyperactive Ras in NF1 associated pro-survival and
RT   malignancy.";
RL   Transl. Oncogenomics 5:1-7(2012).
//
RX   PubMed=24726063; DOI=10.1186/1756-9966-33-33; PMCID=PMC4022359;
RA   Koelsche C., Renner M., Hartmann W., Brandt R., Lehner B.,
RA   Waldburger N., Alldinger I., Schmitt T., Egerer G., Penzel R.,
RA   Wardelmann E., Schirmacher P., von Deimling A., Mechtersheimer G.;
RT   "TERT promoter hotspot mutations are recurrent in myxoid liposarcomas
RT   but rare in other soft tissue sarcoma entities.";
RL   J. Exp. Clin. Cancer Res. 33:33.1-33.8(2014).
//
RX   PubMed=28469964; PMCID=PMC5411799;
RA   Guo J.-M., Grovola M.R., Xie H., Coggins G.E., Duggan P., Hasan R.,
RA   Huang J.-L., Lin D.W., Song C., Witek G.M., Berritt S., Schultz D.C.,
RA   Field J.;
RT   "Comprehensive pharmacological profiling of neurofibromatosis cell
RT   lines.";
RL   Am. J. Cancer Res. 7:923-934(2017).
//
RX   PubMed=32642732; DOI=10.1093/noajnl/vdz049; PMCID=PMC7317054;
RA   Pemov A., Li H., Presley W., Wallace M.R., Miller D.T.;
RT   "Genetics of human malignant peripheral nerve sheath tumors.";
RL   Neurooncol. Adv. 2:i50-i61(2020).
//
RX   PubMed=36818284; DOI=10.1016/j.isci.2023.106096; PMCID=PMC9929861;
RA   Magallon-Lorenz M., Terribas E., Ortega-Bertran S., Creus-Bachiller E.,
RA   Fernandez M., Requena G., Rosas I., Mazuelas H., Uriarte-Arrazola I.,
RA   Negro A., Lausova T., Castellanos E., Blanco I., DeVries G.H.,
RA   Kawashima H., Legius E., Brems H., Mautner V.-F., Kluwe L., Ratner N.,
RA   Wallace M.R., Fernandez-Rodriguez J., Lazaro C., Fletcher J.A.,
RA   Reuss D.E., Carrio M., Gel B., Serra E.;
RT   "Deep genomic analysis of malignant peripheral nerve sheath tumor cell
RT   lines challenges current malignant peripheral nerve sheath tumor
RT   diagnosis.";
RL   iScience 26:106096.1-106096.22(2023).
//